Skip to main content

Heartflow, Inc. (HTFL) Stock Analysis

SellVALUE-TRAP 3/5Moderate Confidence

Healthcare · Health Information Services

Sell if holding. Engine safety override at $26.76: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Elevated put/call ratio: 1.67; Below-average business quality.

Heartflow provides AI-powered software for non-invasive coronary artery disease (CAD) diagnosis, applying computational fluid dynamics to CCTA images to generate Heartflow FFRCT Analysis, Plaque Analysis, and RoadMap Analysis. Revenue is generated on a pay-per-click basis; FFRCT... Read more

$26.76+21.0% A.UpsideScore 5.3/10#10 of 13 Health Information Services
QualityF-score4 / 9FCF yield-2.12%
Stop $24.74Target $32.19(analyst − 13%)A.R:R 1.4:1
Analyst target$37.00+38.3%6 analysts
$32.19our TP
$26.76price
$37.00mean
$40

Sell if holding. Engine safety override at $26.76: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Elevated put/call ratio: 1.67; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

Val5.3Qual3.1Grw10.0Mom5.2Sent7.5Ins3.1Peer2.6Tech6.6Risk2.75.3OVERALL

Recent Developments — Heartflow, Inc.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Recent Analyst detected in news
Risks
Concentration risk — Product: Heartflow FFRCT Analysis (98.0%)
Quality below floor (3.1 < 4.0)
Value-trap signals (3/5): Margin compression (op margin -157.9%), Material insider selling (4 sells, 0.04% of cap), Negative free cash flow

Key Metrics

P/E (TTM)—
P/E (Fwd)-100.6
Mkt Cap$2.3B
EV/EBITDA-32.2
Profit Mgn-58.4%
ROE-135.3%
Rev Growth41.3%
Beta—
DividendNone
Rating analysts12

Quality Signals

Piotroski F4/9MoatNarrow

Options Flow

P/C1.67bearish
IV78%elevated
Max Pain$15-43.9% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHProductHeartflow FFRCT Analysis98%
    10-K Item 1A: 'Our revenue is currently generated almost entirely from the sales of only one product, Heartflow FFRCT Analysis... As of December 31, 2025, our Heartflow FFRCT Analysis represented 98% of our total revenue.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
0.0
Quality Rank
0.4
Growth Rank
8.5
Industry growth leader

Volatile — 7.6% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Debt Equity
0.0
Implied Vol
0.4
Put Call
2.2
Max Pain Risk
3.0
Short Interest
6.3
Days To Cover
7.1
Elevated put/call: 1.67High IV: 78%Above max pain $15Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Unprofitable operations — net margin -58.4%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Piotroski F
4.4
Moat
5.8
Current Ratio
7.4
Gross Margin
10.0
Cash-burning: FCF -25% of revenueRule of 40: 16 (fail)
GatesA.R:R 1.4 < 1.5@spotMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.2>=4.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.50EARNINGS PROXIMITY 85d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
40 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MASupport $24.77Resistance $33.38

Price Targets

$25
$32
A.Upside+20.3%
A.R:R1.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.1 < 4.0)
! Value-trap signals (3/5): Margin compression (op margin -157.9%), Material insider selling (4 sells, 0.04% of cap), Negative free cash flow
! Reward/Risk 1.4:1 at current price — below 1.5:1 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-13 (85d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HTFL stock a buy right now?

Sell if holding. Engine safety override at $26.76: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Elevated put/call ratio: 1.67; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $24.74. Score 5.3/10, moderate confidence.

What is the HTFL stock price target?

Take-profit target: $32.19 (+21.0% upside). Prior stop was $24.74. Stop-loss: $24.74.

What are the risks of investing in HTFL?

Concentration risk — Product: Heartflow FFRCT Analysis (98.0%); Quality below floor (3.1 < 4.0); Value-trap signals (3/5): Margin compression (op margin -157.9%), Material insider selling (4 sells, 0.04% of cap), Negative free cash flow.

Is HTFL overvalued or undervalued?

Heartflow, Inc. trades at a P/E of N/A (forward -100.6). TrendMatrix value score: 5.3/10. Verdict: Sell.

What do analysts say about HTFL?

12 analysts cover HTFL with a consensus score of 4.1/5. Average price target: $37.

What does Heartflow, Inc. do?Heartflow provides AI-powered software for non-invasive coronary artery disease (CAD) diagnosis, applying computational...

Heartflow provides AI-powered software for non-invasive coronary artery disease (CAD) diagnosis, applying computational fluid dynamics to CCTA images to generate Heartflow FFRCT Analysis, Plaque Analysis, and RoadMap Analysis. Revenue is generated on a pay-per-click basis; FFRCT Analysis represented 98% of total revenue as of December 31, 2025, with more than 1,465 U.S. accounts. No single customer accounts for 10% or more of revenue.

Related stocks: WAY (Waystar Holding Corp.) · HQY (HealthEquity, Inc.) · HNGE (Hinge Health, Inc.) · MMED (MiniMed Group, Inc.) · PRVA (Privia Health Group, Inc.)